Related Experiment Video
Updated: Dec 23, 2025

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Interim Guidelines on Antiviral Therapy for COVID-19
Sun Bean Kim1, Kyungmin Huh2, Jung Yeon Heo3
1Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Insights
This guideline reviews potential antiviral and drug therapies for Coronavirus disease 2019 (COVID-19). It synthesizes in vivo, in vitro, and clinical data to inform treatment strategies beyond supportive care.
Area of Science:
- Infectious Diseases
- Virology
- Public Health
Background:
- Coronavirus disease 2019 (COVID-19) emerged in late 2019 and rapidly spread globally.
- As of April 16, 2020, Korea reported over 10,000 cases and 200 deaths.
- Clinical presentations of COVID-19 range from asymptomatic to severe conditions like pneumonia and organ failure.
Purpose of the Study:
- To provide a guideline on potentially effective antiviral and drug therapies for COVID-19.
- To inform clinicians and researchers on treatment options beyond supportive care.
- To consolidate evidence from in vivo, in vitro, and clinical studies.
Main Methods:
- Review of in vivo and in vitro research on COVID-19 therapies.
- Analysis of clinical experiences and treatment data from various countries.
- Guideline development based on synthesized scientific evidence.
Main Results:
- No standard antiviral therapy regimen is established for COVID-19.
- Supportive care remains a cornerstone of COVID-19 management.
- Various antiviral and drug therapies show potential based on preliminary research and clinical observations.
Conclusions:
- Further research and clinical trials are needed to establish definitive COVID-19 treatment protocols.
- This guideline offers a summary of current knowledge on potential therapeutic interventions.
- Evidence-based therapeutic strategies are crucial for managing the COVID-19 pandemic.
Abstract:
Since the first case was reported in Wuhan, Hubei Province, China on December 12, 2019, Coronavirus disease 2019 (COVID-19) has spread widely to other countries since January 2020. As of April 16, 2020, 10635 confirmed cases have been reported, with 230 deaths in Korea. COVID-19 patients may be asymptomatic or show various clinical manifestations, including acute symptoms such as fever, fatigue, sore throat; pneumonia presenting as acute respiratory distress syndrome; and multiple organ failure. As COVID-19 has such varied clinical manifestations and case fatality rates, no standard antiviral therapy regimen has been established other than supportive therapy. In the present guideline, we aim to introduce potentially helpful antiviral and other drug therapies based on in vivo and in vitro research and clinical experiences from many countries.
Related Concept Videos
Myocarditis III: Medical Management
Subviral Agents
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Endocarditis III: Medical Management
Retroviruses
Venous Thrombosis III: Interprofessional Care

